Clinical Trials

Ovarian cancer:

  • Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First-Line Platinum-Based Chemotherapy
  • Maintenance with Niraparib Versus Placebo in Patients with Platinum-Sensitive Ovarian Cancer (NOVA)
  • A randomized, open-label, multicenter, phase 3 study to evaluate the efficacy and safety of Avelumab (MSB0010718C) in combination with and/or following chemotherapy in patients with previously untreated epithelial ovarian cancer (JAVELIN 100)
  • A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults with Ovarian Cancer and other FOLR1-Positive Solid Tumors
  • A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens (QUADRA)
  • A Phase 1b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination with Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin or Pembrolizumab in Adults with Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, or Endometrial Cancer
  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy (PRIMA)
  • A phase 3, multicenter, randomized, open-label study of Avelumab (MSB0010718C) alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in patients with platinum-resistant / refractory ovarian cancer (JAVELIN 200)

Endometrial cancer:

  • AEZS-108 with Doxorubicin as Second-line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer
  • Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma

Cervical cancer: 

  • VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA VACCINE) Delivered IM Followed by Electroporation with Cellectra®-5p For The Treatment Of Biopsy-Proven CIN 2/3 Or CIN 3 With Documented HPV 16 Or 18
  • A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: THE OUTBACK TRIAL
  • Phase III randomized study of concurrent chemotherapy and pelvic radiation therapy with or without adjuvant chemotherapy in high-risk patients with early-stage cervical carcinoma following radical hysterectomy


  • Cervical and Self-Sample in Screening (CASSIS) Study: Diagnostic Performance of Molecular HPV Testing with the Eve Medical Self-Collection System© for Detecting Cervical Intraepithelial Neoplasia
  • DOvEE project: Diagnosing Ovarian & Endometrial Cancer Early 
  • DOvEEgene: Developing and Validating a Novel Molecular Screening Test for the Early Diagnosis of Cancer of the Uterus, Tubes and Ovaries

For more information regarding clinical trials, please contact us.